Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Stopped early · Phase 3

Conditions studied: Hepatocellular Carcinoma

In brief

This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of participants with inoperable liver cancer and blockage of the portal vein.

Key facts

Study ID

NCT01887717

Run by

Boston Scientific Corporation

People needed

36

Starts

2014-02-27

Expected to finish

2017-05-23

Last updated by the study team

2021-04-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants over 18 years of age, regardless of race or gender
• Advanced unresectable hepatocellular carcinoma with branch portal vein thrombosis (confirmed by non-invasive criteria European Association for the Study of the Liver [EASL]/American Association for the Study of Liver Diseases [AASLD], mandatory by histology in non-cirrhotic participants); can be naive or recurrent HCC after curative treatment ( >6 months before randomization)
• Unilobar disease
• Child Pugh A
• Tumor volume ≤70% of liver volume (determined by visual estimation)
• At least one uni-dimensional HCC target lesion assessable by computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Platelets ≥ 50*10\^3/microliter (µL)
• White blood cell (WBC) ≥1.5*10\^3/microliter (µL)
• Aspartate transaminase (AST)/ alanine aminotransferase (ALT) ≤5 times upper limit of normal
• Creatinine ≤2.0 mg/deciliter (dL)
• Life expectancy >3 months
• Signed informed consent

You may not qualify if…

• Confirmed extra hepatic metastases. Participants with indeterminate hepatic hilar lymph nodes up to 2.5 centimeters (cm) in greatest dimension, or with indeterminate lung nodules (single lesion between 1-1.5 cm, or multiple smaller lesions with a total diameter of ≤2 cm) may be included if metastatic disease is deemed unlikely
• Known contraindication to standard-of-care sorafenib including allergic reaction, pill swallowing difficulty, uncontrolled hypertension or history of cardiac disease, significant GI bleed within 30 days, and renal failure including dialysis
• Evidence of hepatic vein invasion or caval thrombosis
• Evidence of chronic obstructive pulmonary disease
• Indication for any possible curative treatment after multidisciplinary assessment (surgery, ablation, transplantation)
• Previous treatment with sorafenib for more than 4 weeks during the previous 2 months; prior sorafenib-related toxicity
• Initiation of anti-tumor therapy including chemotherapy or investigational drug treatment within 30 days before beginning study
• Prior transarterial chemoembolization (TACE) <6 months prior to screening phase in case of participants progressing from an intermediate to an advanced stage due to occurrence of PVT
• On a transplant list
• History of organ allograft
• Contraindications to angiography or selective visceral catheterization
• History of severe allergy or intolerance to contrast agents, narcotics, sedatives, or atropine that cannot be managed medically
• Prior external beam radiation therapy to the liver
• Evidence of continuing adverse effect of prior therapy
• Active gastrointestinal (GI) bleeding and any bleeding diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents
• Evidence of any disease or condition that would place the participant at undue risk and preclude safe use of TheraSphere treatment
• Females of child-bearing potential must have a negative serum test
• No participation in concurrent clinical trials

Where it is running

• Northwestern Medical Faculty Foundation, Div of Hematology/Oncology — Chicago, Illinois, United States
• Mount Sinai School of Medicine — New York, New York, United States
• Cliniques Universitaires Saint-Luc — Brussels, Belgium
• Paoli-Calmettes Institute — Marseille, France
• UO Radiologia, Ospedali Riuniti di Bergamo — Bergamo, Italy
• Azienda Ospedaliero-Universitaria di Bologna — Bologna, Italy
• ASO-Santa Croce e Carle di Cuneo — Cuneo, Italy
• Fondazione IRCCS Ca Grande — Milan, Italy
• S.C Radiologia Interventistica, A.O.Ospedale Niguarda Ca Granda — Milan, Italy
• Fondazione Istituto Nazionale Tumori di Milano — Milan, Italy
• Azienda Ospedaliera Ospedali Riuniti "Villa Sofia-Cervello" — Palermo, Italy
• University of Pisa — Pisa, Italy
• Policlinico A. Gemelli — Rome, Italy
• Hospital Clínic Barcelona. IDIBAPS. CIBEREHD. Liver Unit — Barcelona, Spain
• Bulevar Sur s/n — Madrid, Spain
• Hospital Universitario Puerta de Hierro, Gastroenterology & Hepatology Dept — Madrid, Spain
• Hospital Universitari i Politecnic la Fe — Valencia, Spain
• University Hospitals Birmingham NHS Foundation Trust — Birmingham, United Kingdom
• Royal Free London NHS Foundation Trust — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.